Introduction: Chronic obstructive pulmonary disease (COPD) is a common cause of precapillary pulmonary hypertension (PH). This complication may be overlooked in patients with COPD, as symptoms frequently are attributed to ventilatory limitation. Predictors of PH may identify patients with increased risk of morbidity and mortality. Objective: The aims of this COPD study were to (i) evaluate the relationship between mean pulmonary artery pressure (mPAP) and PaO 2 , (ii) identify significant predictors of mPAP and PaO 2 and (iii) use PaO 2 as a marker of PH. Methods: Altogether 95 COPD patients with mild to very severe airway obstruction and without left ventricular (LV) dysfunction were included. Pulmonary function tests, right heart catheterizations and exercise tests with blood gases were performed. Results: Multivariate regression analyses showed that only PaO 2 was a significant predictor of mPAP. FEV 1 and mPAP were significant predictors of PaO 2 both at rest and at peak exercise. PaO 2 at peak exercise was better to identify pulmonary hypertension than PaO 2 at rest. By combining PaO 2 at rest and peak exercise, it was possible to predict PH with a detection rate of 76% and a false-positive rate of 24%. Conclusion: In an outpatient COPD population where LV disease was thoroughly excluded, we observed that only PaO 2 was a significant predictor of mPAP. PaO 2 at rest and peak exercise below 9.5 kPa (71 mmHg) and 8.5 kPa (64 mmHg), respectively, indicates the need for further evaluation of coexisting PH. ª
Introduction
Chronic obstructive pulmonary disease (COPD) is a common cause of pre-capillary pulmonary hypertension (PH). 1 However, this complication may be overlooked in COPD patients, as symptoms are attributed to ventilatory limitation. The PH due to COPD is often mild to moderate, 2, 3 but is nevertheless associated with increased morbidity and mortality. 4 We have previously reported that PH is quite frequent in an outpatient COPD cohort 5 and recommended to pay attention to this complication. When evaluating COPD patients, predictors of PH should be specifically assessed, and the present study focuses on variables readily available in a pulmonary outpatient clinic. In this aspect, hypoxia is important, because of its association with the development of PH. 6 Vasoconstriction caused by alveolar hypoxia, as well as remodeling of the small pulmonary arteries, are important parts of the pathological process. 7e9 Hypoxemia at rest is associated with poorer prognosis. 10 Preceding respiratory failure, many patients experience hypoxemia during exercise, which may represent an early sign of compromised pulmonary circulation. In order to evaluate the relationship between PH and hypoxemia, we will focus on arterial oxygen tension (PaO 2 ) both at rest and during exercise.
Smoking is a common risk factor of both COPD and cardiovascular disease. Prior studies of PH in COPD have reported a high prevalence of left ventricular (LV) dysfunction, characterized by elevated pulmonary capillary wedge pressure (PCWP). 11e13 This contributes to elevated mean pulmonary artery pressure (mPAP) of the postcapillary type. To avoid this, we have recruited stable COPD patients with a thorough exclusion of LV dysfunction to focus only on the pre-capillary PH.
The present study has recruited ordinary COPD patients from a local pulmonary outpatient clinic, whereas prior invasive studies of PH in COPD often have recruited highly preselected patients referred to specialized PH-centers or transplant evaluation.
The aims of this study were thus to (i) evaluate the relationship between mPAP and PaO 2 , (ii) identify significant predictors of mPAP and PaO 2 and (iii) use PaO 2 as a marker of PH.
Methods

Study population
During the period 2006e10, consecutive patients with stable COPD were invited to a cross sectional study at the Outpatient Department of Pulmonary Medicine at Oslo University Hospital, Aker. 5 Patients aged 40e75 years, with a smoking history of at least 10 pack-years and a minimum of eight weeks since last exacerbation, were asked to participate. The COPD diagnosis was verified by spirometry performed before and after bronchodilatation according to the GOLD guidelines. 14 Exclusion criteria included all pulmonary diseases other than COPD or emphysema. Obstructive sleep apnea syndrome, pulmonary embolism and severe systemic hypertension, as well as the use of beta blockers and anticoagulants or the inability to exercise on a bicycle were reasons for exclusion. Prior to inclusion all patients were examined by a cardiologist to exclude coronary or valvular disease, LV dysfunction or arrhythmia. Electrocardiogram at rest and during exercise was performed for all patients, echocardiography only in those with heart murmur or untreated mild systemic hypertension. Fig. 1 is a flow chart describing the inclusion process.
Study protocol
Patients underwent the test program over two days. They were instructed to take their regular daily medication. All tests were performed without supplementary oxygen. Spirometry, body plethysmography and transfer factor of the lung for carbon monoxide (DLCO) measurement (Jaeger, MasterScreen PFT, Wurtsburg, Germany) were performed with the patient sitting upright. DLCO was measured in patients who had forced vital capacity (FVC) !1.5 L using single breath method. 15 Norwegian reference values for spirometry 16 and DLCO 17 were used, for static lung volumes European reference values were applied. 18 Arterial blood samples were obtained from a radial artery cannula inserted under local anesthesia. Blood gases at rest were first obtained with the patient in supine position and then sitting upright on the cycle ergometer. During exercise, blood gases were obtained every fourth minute and at peak exercise. All sample syringes (Portex, Smiths Medical, Keene, USA) were kept on ice until the end of exercise and then analyzed (Cobas b 221, Roche, Indianapolis, USA). Exercise test was performed on an electronically braked cycle ergometer (Ergoline Variobike 550, Jaeger, Germany). A stepwise incremental protocol was applied with 4 min of unloaded pedaling, 4 min of 25 W, followed by an increase of 10 W every second minute until exhaustion.
Right heart catheterization (RHC) (Mac-Lab, GE Healthcare, Milwaukee, USA) was performed with the patient in the supine position. A 7F SwaneGanz catheter was inserted in the medial antecubital or femoral vein and positioned in the pulmonary artery under guidance of fluoroscopy. Pressure transducers were balanced against the atmospheric pressure at right atrial level. Pressure measurements were made during breath-hold at end-expiration. Cardiac output (CO) was measured by thermodilution technique, averaging three or five output measurements. 5 Pulmonary artery pressures were measured at rest and PH was defined as mPAP ! 25 and PCWP 15 mmHg. 19 Doppler echocardiography (Vivid 7, GE Vingmed Ultrasound, Horten, Norway) was performed during breath-hold at end-expiration from left parasternal long-and short-axis and apical four-chamber view.
The study has been performed according to the Helsinki Declaration and approved by the Regional Ethical Committee. Written informed consent was obtained from all participants.
Statistical analyses
All analyses were performed using IBM SPSS Statistics, version 19. Continuous variables were reported as mean (SD). Independent sample t-test was used to compare mean values for two groups. Paired sample t-test was used to compare the mean difference in the supine and sitting position within the same group. One-way ANOVA with Bonferroni correction was used to compare more than two groups. A significance level of two-tailed p values <0.05 was used for all analyses.
Normality distribution for the dependent variables in Table 4 was evaluated by visual inspection and ShapiroeWilk test. Multiple linear regression analyses were used to determine independent predictors of mPAP and PaO 2 . All significant univariate variables were entered in the full model. Thereafter, backward stepwise eliminations were performed for non-significant (p > 0.05) variables.
Receiver operating characteristic curve analysis (ROC) was performed to test the diagnostic accuracy for discrimination of COPD patients with PH from those without and to determine optimal cut-off values for PaO 2 .
Results
The demographic characteristics are presented in Table 1 , classified by severity in the GOLD stages. 14 No significant differences were found in gender, age, height or smoking habits between the different stages. Body mass index (BMI) was lower in patients with the most severe disease, stage IV, compared to stages II and III. As expected, variables describing pulmonary function were all different between the GOLD stages.
A gradual increase in mPAP was observed with increasing COPD severity (Table 1) . PH was observed in 25 subjects (26%), all but one had mild to moderate disease. Nineteen and five patients had mPAP in the range 25e29 and 30e39 mmHg, respectively. The highest mPAP measured was 40 mmHg and observed in one patient only. When patients were classified by the presence of PH, there were no differences regarding demographic data, but significant differences in pulmonary function. 5 All subjects had PCWP below 15 mmHg, consistent with the exclusion of patients with LV dysfunction.
Respiratory failure, defined as PaO 2 <8 kPa, was observed in 14 patients and seven of these qualified for long term oxygen treatment (LTOT). Ambulatory oxygen was used by four patients. Alfa 1 -antitrypsin deficiency was observed in altogether four patients; one in GOLD stages II and III and two in stage IV. A mean (SD) tobacco consumption of 41 (19) pack-years was reported for the total group. Active smoking was reported in 32% of the subjects, while 68% were ex-smokers. Systemic hypertension and diabetes mellitus were present in 35% and 8% of the subjects, respectively, but did not vary significantly with GOLD stages or with the presence of PH. Regular use of inhaled medication was observed in 93% of the study population. Combination therapy with long-acting beta 2 -stimulators and inhaled corticosteroids was used by 64%, beta 2 -stimulators by 64% and anticholinergic medication by 80%. Theophyllin was used by 13%. Oral corticosteroid maintenance therapy was used by 15%, mainly by patients in GOLD stage IV. PaO 2 decreased gradually with COPD severity both at rest and during exercise ( Table 2) . No significant effect of body posture on PaO 2 could be demonstrated, mean PaO 2 (SD) was 9.4 (1.4) in both the supine and sitting positions. A decline in PaO 2 during exercise was observed in 73% of the subjects, whereas 27% experienced no change or an increase in PaO 2 . The mean change in PaO 2 from rest to peak exercise (DPaO 2 ) was most pronounced in GOLD stages III and IV, and patients with most severe hypoxemia at rest experienced the largest fall in PaO 2 during exercise ( Table 2) .
Arterial carbon dioxide tension (PaCO 2 ) increased with advancing GOLD stages both at rest and during exercise ( Table 2) . No difference was found in PaCO 2 comparing supine and sitting positions for the total cohort, mean (SD) was 5.4 (0.7) kPa in both positions. Fig. 2 shows the univariate relationships between mPAP and PaO 2 both at rest and at peak exercise. Significant correlations were observed for both plots. Mean PaO 2 at rest was 8.3 (1.5) kPa in the group with PH, which was significantly lower than 9.8 (1.2) kPa in the group without PH (p < 0.001). At peak exercise, mean PaO 2 was 7.3 (1.9) and 9.3 (1.6) kPa in the group with and without PH, respectively (p < 0.001).
The univariate relations between the independent variables and mPAP, as well as PaO 2 at rest and peak exercise are shown in Table 3 . Significant differences were observed for FEV 1 , residual volume (RV)/total lung capacity (TLC) ratio and heart rate (HR).
Multivariate regression analyses are shown in Table 4 and were performed with gender, age, height and the significant independent variables from Table 3 in the models. The model for mPAP also included PaO 2 at rest and revealed PaO 2 as the only significant predictor, accounting for 35% of the total variance ( Table 4 ). The models for PaO 2 at rest and PaO 2 at peak exercise included mPAP. The adjusted multivariate models for PaO 2 at rest and PaO 2 at peak exercise revealed FEV 1 and mPAP as significant predictors, together accounting for 46 and 56% of the total variance, respectively ( Table 4 ). No first order interactions were observed between the significant independent variables in any of the models. Fig. 3 shows the relationship between PaO 2 at rest and at peak exercise for subjects with and without pulmonary hypertension. We have applied different cut-off values of PaO 2 , in order to obtain optimal detection-and falsepositive rates for prediction of PH. Fig. 4 shows ROC curves for PaO 2 at rest and peak exercise. Area under the curve is 0.77 (95% CI 0.66, 0.88) and 0.81 (95% CI 0.70, 0.93) for PaO 2 at rest and at peak exercise, respectively. With a cut-off value of PaO 2 at rest 9.5 kPa, the detection rate was 80%, the false-positive and false-negative rates were 41 and 20%, respectively. With a cut-off value of PaO 2 at peak exercise 8.5 kPa, the detection rate was 88%, the falsepositive and false-negative rates were 31 and 12%, respectively. By combining the two, a detection rate of 76% and a false-positive and false-negative rate of 24% were obtained.
Discussion
The present study has shown in an outpatient COPD population, where LV disease was thoroughly excluded, that only PaO 2 was a significant predictor of mPAP when adjusted for demographic data and pulmonary obstructive indices. When assessing the presence of PH in COPD, the combined evaluation of PaO 2 at rest and at peak exercise proved useful.
Consistent with numerous previous studies in COPD patients, we observed a clear inverse relationship between mPAP and PaO 2 . 3, 12 This is due to hypoxic vasoconstriction and vascular remodeling of small pulmonary arteries. In our study, only PaO 2 was a significant predictor of mPAP, whereas in a study of COPD patients with end-stage disease evaluated for lung transplantation, both PaO 2 and PaCO 2 were significant predictors. 12 This discrepancy may be explained by the lower PaCO 2 with less variance both in the group with and without PH in our cohort. Indices of airway obstruction failed to predict mPAP. This is in contrast to a study of COPD patients with severe emphysema where FEV 1 , and not PaO 2 , was a predictor of mPAP. 11 However, severely hypoxic patients were excluded from their study and supplementary oxygen was provided during RHC.
DLCO was missing in 20% of patients with PH, in contrast to 7% in patients without PH. Although DLCO correlates with mPAP and PaO 2 , it introduces a bias in multivariate regression analyses by excluding many subjects with severe disease. DLCO was not included in the final model of multiple regression analyses as this would restrict our analyses Data are presented as mean (SD). PaO 2 : arterial oxygen tension; PaCO 2 : arterial carbon dioxide tension; D: difference peak exercise À rest. { : different from GOLD stage II; þ : different from GOLD stage III.
to only 85 patients. However, when we tried to include DLCO in the regression model in Table 4 anyway, it did not reach significance in predicting mPAP. The missing DLCO measurements were related to inability to hold the breath sufficiently and to low FVC which makes the single breath method unreliable. Rebreathing technique for DLCO measurement could possibly have overcome this problem. 30 Although FEV 1 failed to predict mPAP in our study, it was a significant predictor of PaO 2 both at rest and at peak exercise together with mPAP. In a COPD population from Norway, heart rate, FEV 1 % predicted, fat mass index and TLC were found to be significant predictors of PaO 2 at rest, accounting for only 19% of the total variance. 20 In our cohort, their model would account for 36% of the total variance (adjusted R 2 Z 0.355). By including mPAP in the multiple regression analyses, we could demonstrate a substantial improvement in the explained variance for PaO 2 at rest and observed that heart rate was no longer significant.
By clinical evaluation alone it is difficult to identify COPD patients prone to develop PH. Our data suggest that PH should be considered when PaO 2 at rest is below 9.5 kPa in stable COPD patients without LV disease. The cut-off level at rest was higher than we initially expected, as PH in COPD often is associated with respiratory failure. The higher PaO 2 could be related to our strict exclusion criteria, as no patients with LV disease, interstitial parenchymal disease or other diagnoses known to affect gas exchange were included, but should reflect a COPD population of precapillary PH. Our observed mean PaO 2 in subjects with PH was comparable to previous COPD studies. 12,21e24 However, only two of these studies 12, 21 have reported mPAP and PaO 2 on an individual level. Similar to us, they observed surprisingly high PaO 2 in some subjects with PH, suggesting that there is a large variation in PaO 2 . Moreover, patients with PaO 2 >8 kPa when sitting upright at rest, may experience hypoxemia with change of position, activity level or during sleep. Thus, when we incorporated PaO 2 measured at rest in the supine position in our ROC curve analysis, a cut-off value of 9.1 kPa achieved the same sensitivity (80%) as a cut-off value of 9.5 kPa in the sitting position. However, in outpatient clinics, PaO 2 is usually obtained in the sitting position.
The cut-off level of PaO 2 9.5 at rest gave a falsepositive rate as high as 41%. Although PaO 2 at peak Figure 2 The relationships between mean pulmonary artery pressure (mPAP) and (a) PaO 2 at rest; (b) PaO 2 at peak exercise with the corresponding regression lines. B: GOLD stage II; C: GOLD stage III; :: GOLD stage IV. exercise requires more effort to obtain, we observed that it was better to distinguish between patients with and without PH ( Fig. 4 ). By adding a cut-off level of PaO 2 8.5 at peak exercise the false-positive rate was reduced. When we applied these cut-off values to our RHC cohort of 95 subjects, 49 subjects had PaO 2 9.5 kPa at rest. During the exercise test, 36 of these developed PaO 2 8.5 kPa at peak exercise, which identified 19 of the 25 subjects with PH. Of the remaining 17 subjects with PaO 2 9.5 at rest and 8.5 at peak exercise, only nine had mPAP 20 mmHg. Altogether eight subjects had mPAP of 21e24 mmHg and may be at risk of developing PH. A false-positive rate of 24% seems high, but it includes many patients with borderline pathology. To identify two more subjects with PH, the cut-off limit for PaO 2 at rest would have had to be increased to 10.3 kPa. Although this would have increased the detection rate, many patients without PH would have been investigated unnecessarily. To assess whether COPD patients have PH or not, we therefore suggest that patients with PaO 2 9.5 kPa at rest should perform an exercise test. If PaO 2 at peak exercise reaches 8.5 kPa or below, further PH investigation is recommended.
We found normal PCWP in all patients, which is rather unusual in a COPD cohort, as many patients have cardiovascular comorbidity. Reasons for this could be our strict evaluation of patients prior to inclusion. Echocardiography performed in all study patients showed a normal left ventricular ejection fraction indicating a preserved systolic function. Echocardiographic surrogates for LV filling pressures were all within normal limits indicating a normal diastolic function. We cannot entirely rule out the presence of diastolic dysfunction, as some patients have measurements equal to the upper limit of normal. Moreover, PCWP tends to increase with age and a study of patients with suspected idiopathic pulmonary arterial hypertension found higher PCWP in patients aged 65 or older compared to the younger group. 25 However, results from the ASPIRE study have shown no difference in the prevalence of cardiac 
Figure 3
The relationship between PaO 2 at rest and PaO 2 at peak exercise with cut-off values of 9.5 and 8.5 kPa, respectively. Black: mPAP ! 25 mmHg; white: mPAP < 25 mmHg. comorbidities comparing groups with normal and high PCWP in COPD patients with severe PH. 26 Our multivariate analyses are based upon variables obtained in pulmonary outpatient clinics. When variables from echocardiography were entered in the multivariate regression model presented in Table 4 , pulmonary artery acceleration time (p < 0.001), left ventricular transmitral early diastolic velocity/septal mitral annular early diastolic tissue velocity (E/E 0 ) (p Z 0.018) and PaO 2 (p Z 0.001) were significant predictors of mPAP. Although PaO 2 is not the only significant variable in such a model, it still remains a very strong predictor.
Assessment of the pulmonary circulation should also include evaluation of cardiac index (CI). No significant difference in CI was found between the GOLD stages, they were all within normal range. The higher mPAP in stage IV was not paralleled by reduced CI. A hyperkinetic circulation, induced by hypoxemia, may account for this, as patients in GOLD stage IV demonstrated lower PaO 2 and higher heart rate.
Severe PH was observed in only one patient with mPAP of 40 mmHg. This patient had FEV 1 of 47% predicted and may classify as PH out of proportion to pulmonary function. Such a patient is important to identify and should be referred for evaluation regarding targeted pulmonary vascular therapy. 3, 26 The prevalence of severe PH in COPD is still uncertain, but a reported prevalence of 1% 3 fits well with our observation. Currently, there are no treatment options for COPD patients with mild to moderate PH except for antiobstructive treatment and LTOT. However, identifying these patients provides substantial prognostic information 4 as conventional prognostic models for COPD may be different for PH in COPD. 26 
Limitations
Our study population included highly selected COPD patients, representing only 9% of the total COPD population registered in our outpatient clinic. Thus, they are not necessarily representative of the general COPD population with several comorbidities. 27 However, excluding comorbidities that affect LV function allowed us to focus on precapillary PH, as significant post-capillary contribution to elevated mPAP was minimized. Our cohort reflects all stages of COPD recruited from an ordinary outpatient clinic, which contrasts many previous studies of COPD patients with end-stage disease evaluated for transplantation or volume reduction surgery. 11, 12 The exercise test with measurement of PaO 2 and the RHC were performed as two separate examinations. Different body positions may also have influenced the results; 28 the exercise test was performed sitting on a bicycle, whereas RHC was performed in the supine position. However, no effect of body posture on PaO 2 was found in the total cohort. The mode of exercise might have influenced PaO 2 , as PaO 2 at peak exercise is lower on treadmill compared to bicycle. 29 
Conclusion
We have shown, in a COPD population where post-capillary causes for PH have been systematically excluded, that mPAP is closely associated with PaO 2 , leaving indices of obstruction and hyperinflation of less importance. PaO 2 both at rest and peak exercise are closely associated with airflow limitation and pulmonary artery pressure. Manifestation of PaO 2 at rest and at peak exercise below 9.5 and 8.5 kPa, respectively, indicates the need for further diagnostics, as dysfunction of the pulmonary circulation is likely to be present in the majority of these patients. Further studies should be performed in other COPD cohorts to test our cut-off values in relation to the presence of PH.
